Abstract 1110P
Background
Immune checkpoint inhibitors (ICIs) have limited efficacy in advanced melanoma in Asians, and chemotherapy is still an important option. Temozolomide (TMZ) has been recommended in guidelines for treatment of melanoma. SHR-1701 is a bifunctional fusion protein composed of a mAb against PD-L1 fused to the extracellular domain of TGF-β receptor II. Here, we report the safety and efficacy of SHR-1701 combined with TMZ in advanced melanoma.
Methods
In this single-center, phase II study, patients(pts) with advanced melanoma were eligible. Prior ICIs plus TMZ and progressed within 6 months was not permitted. Pts received SHR-1701(30 mg/kg IV Q3W) combined with TMZ (150 mg/m2 IV, Days 1-5 Q3W) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) per RECIST1.1. Secondary endpoints included progression free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. A standard Simon two-stage design was used. If there were more than 5 responses in 21 pts in stage I, the study would continue to 31 pts in stage II.
Results
As of March 31, 2023, 21 pts were enrolled. Various histology subtypes were included (16 acral, 2 mucosal, 2 cutaneous, 1 unknown histology subtype). The median age was 54 years (range, 34-73), most patients were male (52.4%), 18 pts (85.7%) were ECOG PS 1, 15 pts (71.4%) were stage IV. Received previous 0/1/2 lines of systemic treatment were 14(66.7%)/4(19.0%)/3(14.3%) pts. The median follow-up was 4.4 months(range, 0.5 to 12.7 months). At the data cutoff, 12 pts remained on treatment. Of 16 evaluable pts, 7 pts had partial response, and 6 pts had stable disease. The unconfirmed ORR and DCR were 43.8% and 81.3%, respectively. After treatment, 3 pts with solitarily metastatic lesions received curative surgery. Of 21 pts, the incidence of treatment-related adverse events (TRAEs) was 47.6%, most commonly anemia, γ-glutamyltransferase increase and rash (14.3% each). The incidence of grade 3 TRAEs was 14.3%. No grade ≥ 4 TRAEs occurred.
Conclusions
SHR-1701 plus TMZ showed promising antitumor activity in advanced melanoma pts, and was generally well tolerated.
Clinical trial identification
NCT05106023; released in November 3, 2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13
1119P - Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
Presenter: Teresa Amaral
Session: Poster session 13